Drug Trial Radar · NCT07049926
Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)
Last checked: Nov 20, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
140
Planned (sponsor's estimate)
Start
Jul 20, 2025
Primary completion
Oct 26, 2031
Study completion Oct 26, 2031
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- Collaborators
- Exelixis
- First posted
- Jul 3, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 120 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Substudy 03C is part of a larger research study that is testing experimental treatments for renal cell carcinoma (RCC). The larger study is the umbrella study (U03). The goal of substudy 03C is to evaluate the safety and efficacy of experimental combinations of investigational agents in participants with clear cell renal cell carcinoma (ccRCC) who have recurrent disease during or after anti-programmed cell death 1/programmed cell death ligand 1 (PD-\[L\]1) adjuvant therapy. This substudy will have two phases: a safety lead-in phase and an efficacy phase. The safety lead-in phase will be used to demonstrate a tolerable safety profile for the combination of investigational agents. There will be no hypothesis testing in this study
Conditions
- Renal Cell Carcinoma
Interventions
BelzutifanDrug
Oral Tablet
ZanzalintinibDrug
Oral Tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety Lead In Phase: Number of participants who experience one or more dose-limiting toxicities (DLTs)Time frame: Up to approximately 21 days
- Safety Lead In Phase: Number of participants who experience one or more adverse events (AEs)Time frame: Up to approximately 74 months
- Safety Lead In Phase: Number of participants who discontinue study treatment due to an AETime frame: Up to approximately 74 months
- Efficacy Phase: Number of participants who experience one or more DLTsTime frame: Up to approximately 21 days
- Efficacy Phase: Number of participants who experience one or more AEsTime frame: Up to approximately 74 months
- Efficacy Phase: Number of participants who discontinue study treatment due to an AETime frame: Up to approximately 74 months
- Efficacy Phase: Objective Response Rate (ORR)Time frame: Up to approximately 74 months
Locations
33 sites in 8 countries. Site status is shown where the registry gives one.
UCSF Medical Center at Mission Bay ( Site 5008)
San Francisco, California · Recruiting
Perlmutter Cancer Center at NYU Langone Hospital - Long Island ( Site 5026)
Mineola, New York · Recruiting
Laura and Isaac Perlmutter Cancer Center ( Site 5016)
New York, New York · Recruiting
Memorial Sloan Kettering Cancer Center ( Site 5002)
New York, New York · Recruiting
Duke Cancer Institute ( Site 5015)
Durham, North Carolina · Recruiting
UPMC Cancer Center/Hillman Cancer Center ( Site 5017)
Pittsburgh, Pennsylvania · Recruiting
Vanderbilt University Medical Center ( Site 5004)
Nashville, Tennessee · Recruiting
Centro de Estudios Clínicos SAGA ( Site 6110)
Santiago, Region M. de Santiago, Chile · Recruiting
CDIEM ( Site 6114)
Santiago, Region M. de Santiago, Chile · Recruiting
Bradfordhill ( Site 6101)
Santiago, Region M. de Santiago, Chile · Recruiting
C.H.U. de Strasbourg Hopital de Hautepierre ( Site 5203)
Strasbourg, Bas-Rhin, France · Recruiting
Institut Claudius Regaud ( Site 5200)
Toulouse, Haute-Garonne, France · Recruiting
Gustave Roussy ( Site 5202)
Villejuif, Île-de-France Region, France · Recruiting
Centre Eugene Marquis ( Site 5205)
Rennes, Ille-et-Vilaine, France · Recruiting
Institut De Cancerologie De Lorraine ( Site 5204)
Vandœuvre-lès-Nancy, Meurthe-et-Moselle, France · Recruiting
Rambam Health Care Campus ( Site 5500)
Haifa, Israel · Recruiting
Rabin Medical Center ( Site 5502)
Petah Tikva, Israel · Recruiting
Sheba Medical Center ( Site 5501)
Ramat Gan, Israel · Recruiting
Sourasky Medical Center ( Site 5503)
Tel Aviv, Israel · Recruiting
Centrum Onkologii im. Prof. Franciszka Lukaszczyka ( Site 6201)
Bydgoszcz, Kuyavian-Pomeranian Voivodeship, Poland · Recruiting
Narodowy Instytut Onkologii im. Marii Skłodowskiej Curie ( Site 6203)
Warsaw, Masovian Voivodeship, Poland · Recruiting
Uniwersyteckie Centrum Kliniczne ( Site 6202)
Gdansk, Pomeranian Voivodeship, Poland · Recruiting
Severance Hospital ( Site 5802)
Seoul, South Korea · Recruiting
Asan Medical Center ( Site 5800)
Seoul, South Korea · Recruiting
Samsung Medical Center ( Site 5801)
Seoul, South Korea · Recruiting
Hospital Universitari Vall d'Hebron ( Site 5300)
Barcelona, Spain · Recruiting
HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑON ( Site 5302)
Madrid, Madrid, Comunidad de, Spain · Recruiting
Hospital Universitario Ramon y Cajal ( Site 5301)
Madrid, Madrid, Comunidad de, Spain · Recruiting
Velindre Cancer Centre ( Site 5407)
Cardiff, United Kingdom · Recruiting
The Christie NHS Foundation Trust ( Site 5400)
Manchester, United Kingdom · Recruiting
Western General Hospital ( Site 5402)
Edinburgh, Edinburgh, City of, United Kingdom · Recruiting
The Beatson West of Scotland Cancer Centre ( Site 5405)
Glasgow, Glasgow City, United Kingdom · Recruiting
St Bartholomew's Hospital ( Site 5401)
London, London, City of, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.